Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIO-TECHNE CORPORATION

(TECH)
  Report
Real-time Estimate Cboe BZX  -  10:21 2022-12-05 am EST
81.24 USD   -4.08%
07:01aBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
PR
12/02Bio-techne and oxford nanopore technologies partner to bring innovative reproductive health and carrier screening solutions to the market
AQ
12/01Bio-Techne Teams Up With Oxford Nanopore Technologies for Reproductive Health Testing Projects
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Bio-Techne Corporation Presents at 2022 Wells Fargo Healthcare Conference, Sep-07-2022 09:10 AM

09/07/2022 | 09:10am EST
All right. Great. So I am Tim Daley, Senior Analyst for the Life Science Tools, Diagnostics and Pharma Services sector here at Wells Fargo. I want to thank everybody for attending the 2022 Wells...


ę S&P Capital IQ 2022
All news about BIO-TECHNE CORPORATION
07:01aBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION ..
PR
12/02Bio-techne and oxford nanopore technologies partner to bring innovative reproductive he..
AQ
12/01Bio-Techne Teams Up With Oxford Nanopore Technologies for Reproductive Health Testing P..
MT
11/30BIO-TECHNE CORPORATION : SPLIT: 4 of 1
FA
11/29Bio-Techne to Seek M&A
CI
11/29Transcript : Bio-Techne Corporation Presents at 5th Annual Evercore ISI Healt..
CI
11/28BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
PR
11/17Transcript : Bio-Techne Corporation Presents at Stephens Annual Investment Co..
CI
11/17Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human P..
CI
11/17Namocell highlighted in nature publication for efficient single cell cloning of human p..
PR
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Financials (USD)
Sales 2023 1 202 M - -
Net income 2023 293 M - -
Net cash 2023 176 M - -
P/E ratio 2023 48,1x
Yield 2023 0,52%
Capitalization 13 294 M 13 294 M -
EV / Sales 2023 10,9x
EV / Sales 2024 9,44x
Nbr of Employees 3 000
Free-Float 99,2%
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 84,69 $
Average target price 105,08 $
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel Chief Financial Officer
Robert V. Baumgartner Chairman
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Randolph C. Steer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION-34.52%13 294
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727